TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ).
CARsgen Therapeutics Holdings Ltd. announced that the National Medical Products Administration of China has accepted its New Drug Application for satricabtagene autoleucel (satri-cel), an autologous CAR T-cell product targeting Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma. This development is based on successful Phase II clinical trial results and marks a significant step in CARsgen’s efforts to expand satri-cel’s application in cancer treatment. The acceptance of the NDA and the ongoing trials for satri-cel, including those for pancreatic cancer, highlight CARsgen’s strategic positioning in the biopharmaceutical industry, potentially impacting its market presence and offering new treatment options for patients.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases. The company has comprehensive capabilities in CAR T-cell research and development, including target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen is committed to improving the safety and efficacy of CAR T-cell therapies while reducing treatment costs.
Average Trading Volume: 3,301,389
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.53B
Learn more about 2171 stock on TipRanks’ Stock Analysis page.